Design Therapeutics Proxy Statement Filed
Ticker: DSGN · Form: DEF 14A · Filed: Apr 24, 2025 · CIK: 1807120
| Field | Detail |
|---|---|
| Company | Design Therapeutics, Inc. (DSGN) |
| Form Type | DEF 14A |
| Filed Date | Apr 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Design Therapeutics DEF 14A filed, shareholders vote soon on directors & more.
AI Summary
Design Therapeutics, Inc. filed its definitive proxy statement on April 24, 2025, for its annual meeting of stockholders on June 10, 2025. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of the independent auditor.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and important corporate matters at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy filing providing information to shareholders and does not contain new material financial or operational information.
Key Numbers
- 20250610 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20250424 — Filing Date (Date the proxy statement was submitted to the SEC.)
Key Players & Entities
- Design Therapeutics, Inc. (company) — Registrant
- 0000950170-25-058008 (filing_id) — Accession Number
- 20250424 (date) — Filing Date
- 20250610 (date) — Meeting Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit votes from shareholders for their annual meeting or other special meetings.
When is Design Therapeutics' annual meeting scheduled?
The annual meeting of stockholders for Design Therapeutics, Inc. is scheduled for June 10, 2025.
Who is the filer of this proxy statement?
The filer of this proxy statement is Design Therapeutics, Inc.
What is the filing date of this document?
This definitive proxy statement was filed on April 24, 2025.
What is the company's standard industrial classification?
Design Therapeutics, Inc. falls under the Pharmaceutical Preparations [2834] standard industrial classification.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 regarding Design Therapeutics, Inc. (DSGN).